

Evidence of circulation of West Nile virus in *Culex pipiens* mosquitoes and horses in Morocco

Najlaa Assaid, Laurence Mousson, Sara Moutailler, Soukaina Arich, Khadija Akarid, Maëlle Monier, Cécile Beck, Sylvie Lecollinet, Anna-Bella Failloux, M'Hammed Sarih

► **To cite this version:**

Najlaa Assaid, Laurence Mousson, Sara Moutailler, Soukaina Arich, Khadija Akarid, et al.. Evidence of circulation of West Nile virus in *Culex pipiens* mosquitoes and horses in Morocco. *Biochimica et Biophysica Acta: Biomembranes*, Elsevier, 2020, 205, pp.105414. 10.1016/j.actatropica.2020.105414 . pasteur-02495904

HAL Id: pasteur-02495904

<https://hal-pasteur.archives-ouvertes.fr/pasteur-02495904>

Submitted on 10 Mar 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Evidence of circulation of West Nile virus in *Culex pipiens* mosquitoes and horses in Morocco

Najlaa Assaid^{1,2}, Laurence Mousson³, Sara Moutailler⁴, Soukaina Arich¹, Khadija Akarid², Maëlle Monier⁵, Cécile Beck⁵, Sylvie Lecollinet⁵, Anna-Bella Failloux^{3¶}, M'hammed Sarih^{1¶*}.

¹Institut Pasteur du Maroc, Service de Parasitologie et des Maladies Vectorielles, Place Louis Pasteur, Casablanca 20360, Morocco

²Molecular Genetics and Immunophysiology Research Team, Health and Environment Laboratory, Ain Chock Faculty of Sciences, University of Hassan II Casablanca (UH2C), Casablanca, Morocco.

³Institut Pasteur, Department of Virology, Arboviruses and Insect Vectors, 25-28 rue du Docteur Roux, Paris 75724, France

⁴UMR BIPAR, Animal Health Laboratory, INRAE, ANSES, Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, France.

⁵UMR1161 Virologie, INRAE, ANSES, Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, France

¶These authors contributed equally to this work

*Corresponding author:

E-mail: mhammed.sarih@pasteur.ma (MS)

Emails:

Najlaa Assaid : najlaa.essaid@gmail.com

Laurence Mousson : laurence.mousson@pasteur.fr

Sara Moutailler : sara.moutailler@anses.fr

Soukaina Arich : arichsoukaina@gmail.com

Khadija Akarid : kakarid@yahoo.fr

Cecile Beck : cecile.beck@anses.fr

Maëlle Monier : maelle.monier@anses.fr

Sylvie Lecollinet : sylvie.lecollinet@anses.fr

Anna-Bella Failloux : anna-bella.failloux@pasteur.fr

M'hammed Sarih : mhammed.sarih@pasteur.ma

34 **Abstract**

35 West Nile virus (WNV) is one of the most widely distributed mosquito-borne viruses in the
36 world. In North Africa, it causes human cases of meningoencephalitis with fatalities in
37 Algeria and in Tunisia, whereas only horses were affected in Morocco. The aims of this study
38 were to detect WNV in mosquitoes and to determine seroprevalence of WNV in Moroccan
39 horses by the detection of IgG antibodies. A total of 1,455 mosquitoes belonging to four
40 different species were grouped by collection site, date, and sex with 10 specimens per pool
41 and tested for 38 arboviruses using a high-throughput chip based on the BioMark Dynamic
42 array system. Out of 146 mosquito pools tested, one pool was positive for WNV. This
43 positive pool was confirmed by real time RT-PCR. The serosurvey showed that 33.7%
44 (31/92) of horses were positive for competitive enzyme-linked immunosorbent assay
45 (cELISA) test. The flavivirus-sphere microsphere immunoassay (MIA) test, targeting three
46 flaviviruses (WNV, Usutu virus (USUV) and Tick borne encephalitic virus (TBEV)) showed
47 that 23 sera out of 31 were positive for WNV, two for USUV, two for USUV or WNV, and
48 four for an undetermined flavivirus. Virus neutralization tests with USUV and WNV showed
49 that 28 of 31 sera were positive for WNV and all sera were negative for USUV. This study
50 reports, for the first time, the detection of WNV from *Culex pipiens* mosquitoes in Morocco
51 and its circulation among horses. This highlights that the detection of arboviruses in
52 mosquitoes could serve as an early warning signal of a viral activity to prevent future
53 outbreaks in animals and humans.

54 **Keywords:** Mosquito-borne-viruses; *Culex pipiens*; Horses; WNV; RT-PCR; Serological
55 technics

56
57
58
59
60

61 **1. Introduction**

62 Arboviruses (Arthropod-borne viruses) circulate primarily within an enzootic cycle among
63 wild animals, and spillover transmission to humans and domestic animals have been more
64 frequently reported since two decades (Weaver and Reisen, 2010). Some viruses such as
65 dengue (DENV), chikungunya (CHIKV) and Zika, do not longer need to amplify in animal
66 species to trigger urban epidemic cycles and produce extensive epidemics (Weaver et al.,
67 2018). Factors contributing to these changes are diverse but all point out the preponderant role
68 of human activities in creating ecological niches suitable to vector-borne pathogens, worsened
69 by climate changes offering larger regions suitable to mosquito development (Sutherst, 2004).
70 Among these arboviruses, West Nile virus (WNV; *Flaviviridae*, *Flavivirus*) is maintained in
71 nature in an enzootic transmission cycle between birds and *Culex* mosquitoes. It also infects
72 humans and other animals causing a serious disease and death (Hayes, 2001; Murgue et al.,
73 2001). Birds are considered to be the most important hosts of WNV because they can develop
74 a sufficient viremia to infect mosquitoes after a blood supply (Komar et al., 2003). Humans
75 and horses develop weak and short-term viremia and are considered as dead end hosts
76 (Bowen and Nemeth, 2007). Since its discovery in 1937 in Uganda (Smithburn, 1942), WNV
77 has circulated in Africa mainly associated with mild symptoms (Benjelloun et al., 2016; Sule
78 et al., 2018). The first outbreak describing neuroinvasive symptoms in humans was reported
79 in Israel in 1951 (Murgue et al., 2001). After a silence of more than 30 years, a new
80 emergence, in Romania in 1996 then in Italy and in France respectively in 1998 and in 2000.
81 Since 2004, new strain of the line2 circulates in Europe (Lecollinet et al., 2020). In 1999,
82 WNV was first detected in the Unites States, in New York (Nash et al., 2001) and then spread
83 to the West coast, to Canada and to Central and South America (Banet-Noach et al., 2003;
84 Charrel et al., 2003).

85 Currently, WNV is present in Africa, the Middle East, Europe, Asia, Australia and America
86 and has become the most widely distributed of the encephalitic flaviviruses (Chancey et al.,
87 2015). It possesses one of the highest potentials for re-emergence in North Africa; WNV
88 circulates actively in the region based on two lines of evidence: (i) repeated reports of WNV
89 outbreaks in this region and (ii) the vector *Cx. pipiens* widely present. WNV has been
90 circulating for a very long time in the Mediterranean region (Murgue et al., 2001) affecting
91 mainly humans and horses (Benjelloun et al., 2016; Johnson et al., 2018; Papa, 2019). In
92 Morocco, several outbreaks of WNV have been reported: (i) in 1996 with 94 equine cases
93 including 42 deaths and only one human case (El Harrack et al., 1997; Tber Abdelhaq, 1996),

94 (ii) in September and October of 2003 when WNV circulated among horses in Kenitra
95 (Schuffenecker et al., 2005), (iii) in 2010 in horses (World Animal Health Information
96 Database, 2010 ; Benjelloun et al., 2017; Durand et al., 2016; El Rhaffouli et al., 2013). The
97 two strains of WNV (outbreaks in 1996 and 2003) belonged to clade 1a of lineage 1
98 (schuffenecker et al., 2005). The principal vector of WNV in Europe, Northern USA and
99 North Africa is *Culex pipiens* which is the most widespread vector in temperate regions
100 including North Africa (Amraoui et al., 2012b; Romo et al., 2018). Moreover, two coexisting
101 *Culex pipiens* forms (*pipiens* and *molestus*) are distinguished in temperate areas and
102 correspond to different behavioral, physiological and genetic forms (Harbach, 2012). The
103 form *pipiens* is ornithophilic while *molestus* bites humans and other mammals (Fonseca et al.,
104 2004). These two forms have been proven to hybridize in some regions such as the United
105 States (Fonseca et al., 2004), South Europe (Gomes et al., 2009) and North Africa (Amraoui
106 et al., 2012a; Krida et al., 2015). Hybrids show intermediate trophic preferences assigning
107 them the role of bridge vector for a viral transmission from animals to humans (Fonseca et al.,
108 2004). Targeted surveillance for WNV within mosquito populations offers an opportunity to
109 detect virus prior to the emergence of disease in equine species or human populations
110 (Calzolari et al., 2012). To date, no virological data concerning WNV in mosquitoes from
111 Morocco are available. The aims of this study are: (i) Evaluation of the circulation of
112 mosquito-borne arboviruses in Morocco using a new high-throughput tool based on the
113 BioMark™ Dynamic matrix system capable of screening a large panel of arboviruses in a
114 single experiment. (ii) Detection of WNV past circulation in equids through the confirmation
115 of anti-WNV antibodies in horse serum samples by three serological techniques: cELISA,
116 MIA and microneutralization test (MNT).

117

118 **2. Materials and methods**


119 **2.1. Study sites**

120 The three regions selected for the study are: (i) Mohammedia, a large city located on the coast
121 of the Atlantic Ocean, at 24 km northeast from Casablanca (33°40'25.3"N7°26'42.5"W),
122 where WNV cases were reported in horses in 2010; (ii) Moulay Bouselham
123 34°52'28.7"N6°17'14.5"W, where WNV cases were reported in horses in 2010 and (iii)
124 Tanger 35°46'44.3N5°50'50.1W located on the North of Morocco, where WNV cases were

125 reported in horses in 1996“. Sites of mosquito captures were identified based on records of
126 past circulation areas for WNV (at a period corresponding to a season of high potential
127 transmission risk with high densities of mosquitoes, presence of migratory birds, case reports
128 of meningoencephalitis ...).

129 2.2. Mosquito collection

130 Adult mosquito collections were conducted over four consecutive nights in September and
131 October 2018 using six CDC light traps (Communicable Disease Centers of Atlanta, USA)
132 supplemented with dry ice as a source of CO₂ (from 7:00 pm to 7:00 am) in three regions
133 (Figure 1). The traps were placed approximately 1.5 meters above ground. Traps were
134 dispersed inside houses and near stables and lakes. Live mosquitoes were transported in
135 cages to the laboratory to be identified using identification keys (Brunhes et al., 2000). The
136 identification was carried out on living mosquitoes asleep by the cold on a freeze pack.



137

138

Fig.1. Map of the study area showing the location of mosquito collection cities (●) (Tanger, Moulay Bouselham, Mohammedia) and horse serum collection sites (■) (Casablanca, Mohammedia, Benslimane).

139

140

141 2.3. Mosquito dissection and RNA extraction

142 After morphological identification, mosquitoes were dissected on a freeze pack to isolate the
143 abdomen from the remaining parts of the body. Abdomens of the same species were grouped

144 in pools of 10 individuals and the rest of mosquito bodies were stored individually at -80°C
145 until RNA extraction.

146 Total RNAs were extracted from each pool using Nucleospin RNA kit according to the
147 manufacturer's instructions. Pools were grinded in 350 µL Lysis Buffer and 3.5 µL β-
148 mercaptoethanol using piston stirrer. Total RNA per pool was eluted in 60 µL of RNase free
149 water and stored at -80 °C until use.

150 **2.4. Reverse Transcription and cDNA Pre-Amplification**

151 RNAs were transcribed to cDNA by reverse transcription using the qScript cDNA Supermix
152 kit according to the manufacturer's instructions (Quanta Biosciences, Beverly, USA). For
153 cDNA pre-amplification, the Perfecta Preamp Supermix (Quanta Biosciences, Beverly, USA)
154 was used according to the manufacturer's instructions. These two procedures were performed
155 according to the protocols described by Moutailler et al., 2019.

156 **2.5. High-throughput real-time PCR system**

157 A high throughput epidemiological surveillance method based on a microfluidic system
158 (Fluidigm, South San Francisco, CA, USA) was used according to the protocol described by
159 Moutailler et al., 2019. This technic is more sensitive than real time PCR. This method allows
160 to perform real-time PCR using 96.96 chips, resulting in 9216 individual reactions. The
161 primer sequences / probe sets used in this study are available in Moutailler et al. 2019. A
162 negative water control has been included for each chip. A positive control with cDNA (virus
163 reference material) or DNA (Plasmid) was used. To determine if inhibitors could be present in
164 the sample, DNA from the Escherichia coli strain EDL933 was added to each sample as an
165 internal inhibition control, using gene-specific primers and probes E. coli eae (Nielsen &
166 Andersen, 2003). Data were acquired on the BioMark™ real-time PCR system and analyzed
167 using Fluidigm real-time PCR analysis software to obtain Ct values (Michelet and al., 2014).

168 **2.6. Real time PCR**

169 RNA from WNV positive mosquito pool was screened by real-time PCRs on a StepOne
170 Instrument (Applied Biosystem, Thermo Fisher Scientific, Illkirch, France). Real-time RT-
171 PCR assay targeting a different segment of the WNV genome (5'UTR and part of the capsid
172 gene) (Linke et al., 2007) was performed in a final volume of 25 µL using 5µL of RNA and
173 AgPath-ID™ One-Step RT-PCR Reagents (Thermo Fisher Scientific, France) containing

174 primers and probes at 400 nM and 200nM respectively. Thermal cycling conditions were as
175 follows: 45°C for 10 minutes, 95°C for 10 min, 45 cycles at 95°C for 15 s and 60°C for 1 min.

176 **2.7. Blood sampling and recovery of horse sera**

177 A total of 92 horses were sampled in five different equestrian clubs, located in the region of
178 Casablanca-Mohammedia-Benslimane (area where was declared the last WNV epizootic in
179 Morocco in 2010) (figure1). Horses sampled were more than 2 years old, male and female,
180 and of different breeds; they showed no clinical signs associated with West Nile disease. Each
181 blood sample was collected in dry tubes and transported at +4 ° C to the laboratory where
182 samples were centrifuged. The sera were aliquoted, separated and stored at -20 ° C until use.

183 **2.8. Serological test**

184 **2.8.1. Competitive enzyme-linked immunosorbent assay (cELISA)**

185 The serological diagnosis was made using a cELISA test (ID Screen® West Nile Competition
186 ELISA Kit, ID Vet, France) to give an indication of the presence or absence of anti-WNV
187 antibodies in horses sera. Analysis and interpretation were performed according to the
188 manufacturer's instructions. The optical density was observed and the S/N ratio (optical
189 density of the sample / optical density of the negative control * 100) was calculated. Samples
190 with a S/N ratio of 40% or less were considered positive while those with a S/N ratio
191 comprised between 40 and 50% were considered doubtful, and those with a S/N ratio higher
192 than 50% were considered negative. This test has been used to give an indication of the
193 presence or absence of anti-WNV antibodies in sera, but cross-reactions with other
194 flaviviruses may occur (Beck et al., 2017).

195 **2.8.2. Microsphere immunoassay**

196 Flavivirus microsphere immunoassay (MIA) was performed on cELISA positive samples as
197 described by Beck et al. (2015). Briefly, recombinant soluble ectodomain of WNV envelope
198 (E) glycoprotein (WNV.sE) and the recombinant E domains III (rEDIIIs) of WNV, USUV
199 and TBEV containing virus-specific epitopes were covalently bound to fluorescent beads
200 following the protocol previously described in (Beck et al., 2015; Vanhomwegen et al., 2017).
201 Reactivity against WNV.sE is indicative of the presence of anti-flavivirus antibodies (as with
202 the IDVET cELISA), and WNV.EDIII, TBEV.EDIII and USUV.EDIII allows to distinguish
203 between these flaviviruses.

204 The cut-offs of WNV.sE, WNV.EDIII, and TBEV.EDIII antigens were found to be 17, 54 and
205 61, respectively, as described in (Beck et al., 2015). For USUV, due to no positive horse
206 serum against this disease, the cut-off was determined from the mean of median of
207 fluorescence (MFI) values of 66 negative horse sera plus 3 standard deviations of the mean.
208 The 66 sera used to determine the cut-off were sampled in Poland (35 sera) and Ireland (31
209 sera) and were all found negative with the ID screen West Nile competition kit (IDVet). The
210 MIA results were interpreted according to the following algorithm : (i) a serum was
211 considered positive for WNV (or alternatively for USUV) if it reacted against WNV.sE and
212 WNV.EDIII (of alternatively USUV.EDIII) (ii) In case of positive reactions with several
213 rEDIIIs for viruses belonging to the Japanese encephalitis serocomplex (i.e. USUV and
214 WNV) an animal was considered infected with a specific flavivirus if the corresponding bead
215 coupled to rEDIII generated an MFI at least two-fold greater than that generated with the
216 other beads. If a 2 fold difference could not be achieved, the animal was considered to be
217 infected with WNV or USUV (iii) since TBEV belongs to another serocomplex, a serum was
218 considered positive for TBEV when the TBEV.EDIII MFI was above the cut off (iiii) finally,
219 a sample was considered positive for an undetermined flavivirus if it reacted with WNV.sE
220 but not with any of the EDIIIs.

221 **2.8.3. Seroneutralization tests**

222 Flaviviruses identified by MIA and all undetermined ELISA-positive flavivirus samples were
223 investigated using MNT against WNV and USUV.

224 Neutralizing antibody titers against WNV and USUV were determined by MNT on Vero cells
225 in 96-well cell culture plates, following the protocol described in (Beck et al., 2015), using
226 WNV strain IS-98-ST1 (Genbank ID AF481864.1, provided by P. Desprès, IPP) and USUV
227 strain France 2018. The MNT results were interpreted according to the following rules: (i) A
228 serum was considered positive if cells were protected at the 1:10 serum dilution for WNV and
229 USUV. Owing cross-neutralization between flaviviruses especially in the same serocomplex,
230 we identified the infecting flavivirus by considering the virus with the highest neutralization
231 capacity, and with neutralization titers that differ by at least a four-fold factor (Beck et al
232 2015).

233

234 **3. Results**

235 **3.1. High-throughput screening of mosquito-borne viruses**

236 A total of 1,455 mosquitoes were analyzed. 670 mosquitos were collected from Mohamedia
237 region, all belonging to *Culex pipiens* species, and 780 mosquitoes collected from regions of
238 northern Morocco (Moulay Bouselham-Larache (n = 595) and Tangier (n = 190)) belonging
239 to *Aedes detritus* species (n = 320), *Aedes caspius* (n = 110), *Anopheles maculipennis* (n = 5)
240 and *Culex pipiens* species (n = 160). Among tested pools (146), one pool from Mohammedia
241 area was positive for WNV (see table 1). On the other hand, all the pooled mosquitoes from
242 Tanger and Moulay Bouselham regions were negative (Table 1).

243 **3.2. Real time RT-PCR**

244 The positive pool for WNV was confirmed by a real time RT-PCR targeting a different
245 fragment of the WNV genome.

246 **3.3. Detection of anti-WNV antibodies in horses**

247 In order to determine the WNV seroprevalence in 92 horses, we used three techniques:
248 cELISA which detects anti-flavivirus antibodies, the MIA test which allows to distinguish
249 between the three flavivirus: WNV, USUV and TBEV, and the MNT which allows the
250 confirmation of the presence of anti-WNV antibodies and anti-USUV antibodies.

251 The seroprevalence by cELISA was 33.7% (31/92). The MIA test showed that 25.0% (23/92)
252 were positive for WNV, 2.1% (2/92) were positive for USUV, 4.3% (4/92) were positive for
253 undetermined flavivirus and 2.1% (2/92) were positive for both WNV and USUV (Table 2).

254 The MNT showed that 30.4% (28/92) were positive for WNV with titers between 20 to
255 superior to 320. The results of the two methods were in accordance for the 23 MIA WNV
256 positives. Conversely, 2 samples positive for USUV, 2 positives for both WNV and USUV
257 and one for undetermined flavivirus by MIA were found WNV positive by MNT. All sera
258 were negative for USUV in MNT (Table 3).

259 **3. Discussion**

260 This study reports, for the first time, the detection of WNV in *Culex pipiens* mosquitoes and
261 high seroprevalence rate of WNV infection in horses from Morocco (30% by MNT test). We
262 used the new high-throughput screening method, which examines 38 arboviruses (94 different

263 genotypes/serotypes) in a single experiment (Moutailler et al., 2019). In Morocco, WNV was
264 isolated and sequenced only once during the epizootic of 2003. The viral isolation was
265 performed from a cerebral biopsy of a dead horse (Schuffenecker et al., 2005). In our study,
266 WNV-infected mosquitoes were only found in Mohammedia region and not in Moulay
267 Bouselhame region, probably owing to the low number of specimens examined: 160
268 individuals in Moulay Bouselhame compared to 670 tested in Mohammedia region. We
269 reported a low *Cx. pipiens* infection rate (0.15% (1/670), a result in agreement with other
270 investigations (Engler et al., 2013): 1.2% for *Cx. pipiens* in Tunisia (Monastiri et al., 2018),
271 0.56% for *Cx. perexiguus* in Algeria (Benbetka et al., 2018), 0.24% for *Cx. interrogator* and
272 0.28% for *Cx. nigripalpus* in Chiapas, México (Ulloa et al., 2009). Anti-flavivirus antibodies
273 have been detected by cELISA in 34% (31/92) of horse sera and 100% (31/31) of cELISA
274 positive sera were found reactive to the WNV.sE bead by MIA. These two independent
275 methods corroborated the detection of anti-flavivirus antibodies in horses (Beck et al., 2015).
276 To improve the specificity of flavivirus serological screening, flavivirus positive samples
277 were tested by MIA using WNV.EDIII, USUV.EDIII and TBEV.EDIII antigens which
278 contain virus-specific-epitopes (Beasley et al., 2004; Beck et al., 2015) and by MNT against
279 WNV and USUV. A significant proportion of horses (23/28) were found to be WNV positive
280 by the two technics. Two samples were found positive against USUV in MIA but positive for
281 WNV in MNT. Such discordant results could originate from a lower specificity of the
282 flavivirus EDIII MIA technique. The fact that these sera were tested by MIA with WNV and
283 USUV nonstructural protein 1 (NS1) and were found positive for WNV (data not given)
284 supports this hypothesis. We did not identify the flavivirus involved in 9.7% (3/31) of horse
285 infections evidenced by positive cELISA reactions. As already mentioned by several authors
286 (Beck et al., 2015), WNV cELISA tests lack specificity in the diagnosis of WNV infection. Of
287 31 sera tested positive for anti-WNV IgG by ELISA, only 28 had specific neutralizing
288 antibodies. Benjelloun and his collaborators studied seroprevalence of WNV in different
289 regions of Morocco in 2011. They found a seroprevalence rate of WNV similar to our study
290 35% and 31% respectively by cELISA and MNT (Benjelloun et al., 2017). Another study
291 carried out with 297 military working horses and 231 dogs in Morocco have described,
292 respectively, a rate of 60% and 62% of seroprevalence by cELISA (Durand et al., 2016). This
293 high rate of WNV seroprevalence has also been reported by other team in Tunises and Algeria
294 (Ben Hassine et al., 2014; Lafri et al., 2017). USUV and WNV have been shown to co
295 circulate and share the same vectors (Zannoli and Sambri, 2019); however, we did not detect
296 USUV either in mosquitoes nor in horse sera, while USUV has been shown to circulate in

297 Tunisia and in Morocco (Ayadi et al., 2019; Ben Hassine et al., 2014; Figuerola et al., 2009).
298 For the sera found positive with the ELISA test and negative in WNV and USUV MNTs
299 (3/31), such reactions could correspond to low WNV antibody responses under the detection
300 MNT threshold or to animals infected with other flaviviruses (yellow fever virus, ...).
301 Recently, cELISA positive and WNV MNT negative horses on French pacific islands turned
302 out to be Dengue and Zika-infected. The serological results highlighted the importance of
303 taking into account the risk of circulation of other arboviruses such as dengue, chikungunya
304 and zika viruses, since the vector of these arboviruses, *Ae. albopictus*, was recently
305 established in Morocco (Bennouna et al., 2017) and their ability to transmit these viruses
306 efficiently has been experimentally proven (Amraoui et al., 2019).

307 Our results are in agreement with many arguments for active circulation of WNV in this area
308 of Morocco that are: (i) high abundance of *Cx. pipiens* mosquitoes in a region hosting
309 migratory birds (Jourdain et al., 2007), and (ii) their ability to experimentally transmit WNV
310 (Amraoui et al. 2012). The water reservoirs present in this area would constitute ideal
311 ecological niches for repeated contacts between domestic or migratory birds and mosquitoes,
312 thus allowing the amplification of the virus in an enzootic cycle (Zeller and Murgue, 2001).
313 WNV has been responsible for sporadic outbreaks of disease in countries around the
314 Mediterranean sea since the 1960 (Hubálek and Halouzka, 1999). These have involved
315 infections in humans and/or horses (Zeller et al., 2004). All outbreaks were reported between
316 July and September. The principal vector of WNV in Europe and USA is *Culex pipiens*
317 (Esteves et al., 2005; Kilpatrick et al., 2005). These countries have favorable conditions for
318 maintaining the WNV transmission cycle such as environmental factors and climatic
319 conditions (Rogers and Randolph, 2006). These conditions support virus circulation, and
320 when the density of vector mosquitoes is enhanced and sensitive hosts are available,
321 outbreaks are observed. The high prevalence of antibodies among horses also suggest that
322 substantial circulation of the virus may have occurred during the previous seasons. The
323 observed titer of the positive sera is probably due to re-infections during the previous 2010
324 outbreak or a prolonged and repeated exposure to viruses in endemics areas. These results
325 suggest that WNV was present in Morocco in 2018 without resulting in disease outbreaks
326 among humans or horses, as opposed to in 1996, 2003 and 2010, when cases did occur (El
327 Harrack et al., 1997; El Rhaffouli et al., 2012; Schuffenecker et al., 2005). Absence of
328 outbreaks despite the circulation of the virus could be explained by the acquisition of a

329 protective immunity after the first infection by humans and horses and, possibly by the lack of
330 entomological virus surveillance and asymptomatic underreported cases.

331 Our results strongly suggest that WNV remains silent and spillover events to humans occurs
332 only under favorable ecological conditions. Therefore, understanding ecological factors and
333 environmental conditions leading to WNV outbreak is of major importance. Persistence of
334 WNV in over wintering *Cx. pipiens* is an important mechanism in the maintenance of this
335 arbovirus (Nasci et al., 2001). Thus, WNV is likely to cause future sporadic and foreseeable
336 outbreaks not only in Morocco but along the migratory flyways of birds between Africa and
337 Europe. Virus circulation becomes permanent and is probably maintained by mosquito vector
338 movements and reintroduction of migratory birds.

339 This study brings important data about an active WNV circulation in mosquitoes in Morocco.
340 It is suggested that public health authorities should implement WNV surveillance activities
341 and setting up an entomological surveillance as an early alert system around the
342 Mediterranean Basin to prevent future outbreaks is highly needed.

343 **Acknowledgements**

344 This study was funded by Institut Pasteur of Morocco and Pasteur Institute in Paris. We thank Mr.
345 Abbani Labaoui for his help in the field work and also the managers of the equestrian clubs for the
346 blood samples from horses.

347 **Author contributions**

348 **Conceptualization:** Anna-Bella Failloux, M'hammed Sarih

349 **Formal analysis:** Najlaa Assaid.

350 **Investigation:** Najlaa Assaid, Laurence Mousson, sara Moutailler, Soukaina Arich, Khadija Akharid,
351 Cécile Beck, Sylvie lecollinet,

352 **Methodology:** Anna-Bella Failloux, Laurence Mousson, sara Moutailler, Soukaina Arich, Khadija
353 Akharid, Cécile Beck, Sylvie Lecollinet, Najlaa Assaid, M'hammed Sarih

354 **Supervision:** Anna-Bella Failloux, M'hammed Sarih, Sylvie lecollinet

355 **Validation:** Anna-Bella Failloux, M'hammed Sarih, Sylvie lecollinet

356 **Writing-original draft:** Najlaa Assaid, M'hammed Sarih

357 **Writing-review & editing:** Anna-Bella Failloux, sara Moutailler, Cécile Beck, Sylvie Lecollinet

358

359

360 **References**

- 361 Amraoui, F., Ayed, W.B., Madec, Y., Faraj, C., Himmi, O., Btissam, A., Sarih, M., Failloux, A.-B., 2019.
362 Potential of *Aedes albopictus* to cause the emergence of arboviruses in Morocco. PLoS Negl.
363 Trop. Dis. 13, e0006997.
- 364 Amraoui, F., Krida, G., Bouattour, A., Rhim, A., Daaboub, J., Harrat, Z., Boubidi, S.-C., Tijane, M., Sarih,
365 M., Failloux, A.-B., 2012a. *Culex pipiens*, an experimental efficient vector of West Nile and Rift
366 Valley fever viruses in the Maghreb region. PLoS One 7, e36757.
- 367 Amraoui, F., Tijane, M., Sarih, M., Failloux, A.-B., 2012b. Molecular evidence of *Culex pipiens* form
368 molestus and hybrids pipiens/molestus in Morocco, North Africa. Parasit. Vectors 5, 83.
- 369 Ayadi, T., Hammouda, A., Beck, C., Boulonier, T., Lecollinet, S., Selmi, S., 2019. Flaviviruses in
370 migratory passerines during spring stopover in a desert oasis. Zoonoses Public Health.
- 371 Banet-Noach, Ca., Simanov, L., Malkinson, M., 2003. Direct (non-vector) transmission of West Nile
372 virus in geese. Avian Pathol. 32, 489–494.
- 373 Beasley, D.W., Holbrook, M.R., Da Rosa, A.P.T., Coffey, L., Carrara, A.-S., Phillippi-Falkenstein, K.,
374 Bohm, R.P., Ratterree, M.S., Lillibridge, K.M., Ludwig, G.V., 2004. Use of a recombinant
375 envelope protein subunit antigen for specific serological diagnosis of West Nile virus
376 infection. J. Clin. Microbiol. 42, 2759–2765.
- 377 Beck, C., Desprès, P., Paulous, S., Vanhomwegen, J., Lowenski, S., Nowotny, N., Durand, B., Garnier,
378 A., Blaise-Boisseau, S., Guitton, E., Yamanaka, T., Zientara, S., Lecollinet, S., 2015. A High-
379 Performance Multiplex Immunoassay for Serodiagnosis of Flavivirus-Associated Neurological
380 Diseases in Horses. BioMed Res. Int. 2015. <https://doi.org/10.1155/2015/678084>
- 381 Beck, C., Lowenski, S., Durand, B., Bahuon, C., Zientara, S., Lecollinet, S., 2017. Improved reliability of
382 serological tools for the diagnosis of West Nile fever in horses within Europe. PLoS Negl.
383 Trop. Dis. 11, e0005936.
- 384 Ben Hassine, T., De Massis, F., Calistri, P., Savini, G., BelHaj Mohamed, B., Ranen, A., Di Gennaro, A.,
385 Sghaier, S., Hammami, S., 2014. First detection of co-circulation of West Nile and Usutu
386 viruses in equids in the South-west of Tunisia. Transbound. Emerg. Dis. 61, 385–389.
- 387 Benbetka, S., Hachid, A., Benallal, K.E., Benbetka, C., Khaldi, A., Bitam, I., Harrat, Z., 2018. First field
388 evidence infection of *Culex perexiguus* by West Nile virus in Sahara Oasis of Algeria. J. Vector
389 Borne Dis. 55, 305.
- 390 Benjelloun, A., El Harrak, M., Belkadi, B., 2016. West Nile disease epidemiology in North-West Africa:
391 bibliographical review. Transbound. Emerg. Dis. 63, e153–e159.
- 392 Benjelloun, A., El Harrak, M., Calistri, P., Loutfi, C., Kabbaj, H., Conte, A., Ippoliti, C., Danzetta, M.L.,
393 Belkadi, B., 2017. Seroprevalence of West Nile virus in horses in different Moroccan regions.
394 Vet. Med. Sci. 3, 198–207.
- 395 Bennouna, A., Balenghien, T., El Rhaffouli, H., Schaffner, F., Garros, C., Gardes, L., Lhor, Y.,
396 Hammoumi, S., Chlyeh, G., Fassi Fihri, O., 2017. First record of *Stegomyia albopicta* (= *Aedes*
397 *albopictus*) in Morocco: a major threat to public health in North Africa? Med. Vet. Entomol.
398 31, 102–106.
- 399 Bowen, R.A., Nemeth, N.M., 2007. Experimental infections with West Nile virus. Curr. Opin. Infect.
400 Dis. 20, 293–297.
- 401 Brunhes, J., Rhaim, A., Geoffroy, B., Angel, G., Hervy, J.-P., 2000. Les moustiques de l’Afrique
402 méditerranéenne: logiciel d’identification et d’enseignement.
- 403 Calzolari, M., Gaibani, P., Bellini, R., Defilippo, F., Pierro, A., Albieri, A., Maioli, G., Luppi, A., Rossini,
404 G., Balzani, A., 2012. Mosquito, bird and human surveillance of West Nile and Usutu viruses
405 in Emilia-Romagna Region (Italy) in 2010. PLoS One 7, e38058.
- 406 Chancey, C., Grinev, A., Volkova, E., Rios, M., 2015. The global ecology and epidemiology of West Nile
407 virus. BioMed Res. Int. 2015.
- 408 Charrel, R.N., Brault, A.C., Gallian, P., Lemasson, J.-J., Murgue, B., Murri, S., Pastorino, B., Zeller, H.,
409 De Chesse, R., De Micco, P., 2003. Evolutionary relationship between Old World West Nile

410 virus strains: evidence for viral gene flow between Africa, the Middle East, and Europe.
411 *Virology* 315, 381–388.

412 Durand, B., Haskouri, H., Lowenski, S., Vachiéry, N., Beck, C., Lecollinet, S., 2016. Seroprevalence of
413 West Nile and Usutu viruses in military working horses and dogs, Morocco, 2012: dog as an
414 alternative WNV sentinel species? *Epidemiol. Infect.* 144, 1857–1864.

415 El Harrack, M., Le Guenno, B., Gounon, P., 1997. Isolement du virus West Nile au Maroc. *Virologie* 1,
416 248–9.

417 El Rhaffouli, H., El Harrak, M., Lotfi, C., El Boukhrissi, F., Bajjou, T., Laraqui, A., Hilali, F., Kenfaoui, M.,
418 Lahlou-Amine, I., 2012. Serologic evidence of West Nile virus infection among humans,
419 Morocco. *Emerg. Infect. Dis.* 18, 880.

420 El Rhaffouli, H., Lahlou-Amine, I., Loutfi, C., Laraqui, A., Bajjou, T., Fassi-Fihri, O., El Harrak, M., 2013.
421 Serological evidence of West Nile Virus infection among humans in the southern Provinces of
422 Morocco. *J. Infect. Dev. Ctries.* 7, 999–1002.

423 Engler, O., Savini, G., Papa, A., Figuerola, J., Groschup, M.H., Kampen, H., Medlock, J., Vaux, A.,
424 Wilson, A.J., Werner, D., 2013. European surveillance for West Nile virus in mosquito
425 populations. *Int. J. Environ. Res. Public Health* 10, 4869–4895.

426 Esteves, A., Almeida, A.P.G., Galão, R.P., Parreira, R., Piedade, J., Rodrigues, J.C., Sousa, C.A., Novo,
427 M.T., 2005. West Nile virus in southern Portugal, 2004. *Vector-Borne Zoonotic Dis.* 5, 410–
428 413.

429 Figuerola, J., Baouab, R.E., Soriguer, R., Fassi-Fihri, O., Llorente, F., Jiménez-Clavero, M.A., 2009. West
430 Nile virus antibodies in wild birds, Morocco, 2008. *Emerg. Infect. Dis.* 15, 1651.

431 Fonseca, D.M., Keyghobadi, N., Malcolm, C.A., Mehmet, C., Schaffner, F., Mogi, M., Fleischer, R.C.,
432 Wilkerson, R.C., 2004. Emerging vectors in the *Culex pipiens* complex. *Science* 303, 1535–
433 1538.

434 Gomes, B., Sousa, C.A., Novo, M.T., Freitas, F.B., Alves, R., Côrte-Real, A.R., Salgueiro, P., Donnelly,
435 M.J., Almeida, A.P., Pinto, J., 2009. Asymmetric introgression between sympatric molestus
436 and pipiens forms of *Culex pipiens* (Diptera: Culicidae) in the Comporta region, Portugal. *BMC*
437 *Evol. Biol.* 9, 262.

438 Harbach, R.E., 2012. *Culex pipiens*: species versus species complex—taxonomic history and
439 perspective. *J. Am. Mosq. Control Assoc.* 28, 10–23.

440 Hayes, C.G., 2001. West Nile virus: Uganda, 1937, to New York City, 1999. *Ann. N. Y. Acad. Sci.* 951,
441 25–37.

442 Hubálek, Z., Halouzka, J., 1999. West Nile fever—a reemerging mosquito-borne viral disease in
443 Europe. *Emerg. Infect. Dis.* 5, 643.

444 Johnson, N., Fernández de Marco, M., Giovannini, A., Ippoliti, C., Danzetta, M., Svartz, G., Erster, O.,
445 Groschup, M., Ziegler, U., Mirazimi, A., 2018. Emerging mosquito-borne threats and the
446 response from European and Eastern Mediterranean Countries. *Int. J. Environ. Res. Public*
447 *Health* 15, 2775.

448 Jourdain, E., Schuffenecker, I., Korimbocus, J., Reynard, S., Murri, S., Kayser, Y., Gauthier-Clerc, M.,
449 Sabatier, P., Zeller, H.G., 2007. West Nile virus in wild resident birds, Southern France, 2004.
450 *Vector-Borne Zoonotic Dis.* 7, 448–452.

451 Kilpatrick, A.M., Kramer, L.D., Campbell, S.R., Alleyne, E.O., Dobson, A.P., Daszak, P., 2005. West Nile
452 virus risk assessment and the bridge vector paradigm. *Emerg. Infect. Dis.* 11, 425.

453 Komar, N., Langevin, S., Hinten, S., Nemeth, N., Edwards, E., Hettler, D., Davis, B., Bowen, R.,
454 Bunning, M., 2003. Experimental infection of North American birds with the New York 1999
455 strain of West Nile virus. *Emerg. Infect. Dis.* 9, 311.

456 Krida, G., Rhim, A., Daaboub, J., Failloux, A.-B., Bouattour, A., 2015. New evidence for the potential
457 role of *Culex pipiens* mosquitoes in the transmission cycle of West Nile virus in Tunisia. *Med.*
458 *Vet. Entomol.* 29, 124–128.

459 Lafri, I., Prat, C.M., Bitam, I., Gravier, P., Besbaci, M., Zeroual, F., Ben-Mahdi, M.H., Davoust, B.,
460 Leparac-Goffart, I., 2017. Seroprevalence of West Nile virus antibodies in equids in the North-

461 East of Algeria and detection of virus circulation in 2014. *Comp. Immunol. Microbiol. Infect.*
462 *Dis.* 50, 8–12.

463 Lecollinet, S., Pronost, S., Couplier, M., Beck, C., Gonzalez, G., Leblond, A., Tritz, P., 2020. Viral Equine
464 Encephalitis, a Growing Threat to the Horse Population in Europe? *Viruses* 12, 23.
465 <https://doi.org/10.3390/v12010023>

466 Linke, S., Ellerbrok, H., Niedrig, M., Nitsche, A., Pauli, G., 2007. Detection of West Nile virus lineages 1
467 and 2 by real-time PCR. *J. Virol. Methods* 146, 355–358.

468 Michelet, L., Delannoy, S., Devillers, E., Umhang, G., Aspan, A., Juremalm, M., Chirico, J., van der Wal,
469 F.J., Sprong, H., Boye Pihl, T.P., 2014. High-throughput screening of tick-borne pathogens in
470 Europe. *Front. Cell. Infect. Microbiol.* 4, 103.

471 Monastiri, A., Mechri, B., Vázquez-González, A., Ar Gouilh, M., Chakroun, M., Loussaief, C., Mastouri,
472 M., Dimassi, N., Boughzala, L., Aouni, M., 2018. A four-year survey (2011–2014) of West Nile
473 virus infection in humans, mosquitoes and birds, including the 2012 meningoencephalitis
474 outbreak in Tunisia. *Emerg. Microbes Infect.* 7, 1–10.

475 Moutailler, S., Yousfi, L., Mousson, L., Devillers, E., Vazeille, M., Vega-Rúa, A., Perrin, Y., Jourdain, F.,
476 Chandre, F., Cannet, A., 2019. A new high-throughput tool to screen mosquito-borne viruses
477 in Zika virus endemic/epidemic areas. *Viruses* 11, 904.

478 Murgue, B., Murri, S., Triki, H., Deubel, V., Zeller, H.G., 2001. West Nile in the Mediterranean Basin:
479 1950–2000. *Ann. N. Y. Acad. Sci.* 951, 117–126.

480 Nasci, R.S., Savage, H.M., White, D.J., Miller, J.R., Cropp, B.C., Godsey, M.S., Kerst, A.J., Bennett, P.,
481 Gottfried, K., Lanciotti, R.S., 2001. West Nile virus in overwintering *Culex* mosquitoes, New
482 York City, 2000. *Emerg. Infect. Dis.* 7, 742.

483 Nash, D., Mostashari, F., Fine, A., Miller, J., O’Leary, D., Murray, K., Huang, A., Rosenberg, A.,
484 Greenberg, A., Sherman, M., 2001. The outbreak of West Nile virus infection in the New York
485 City area in 1999. *N. Engl. J. Med.* 344, 1807–1814.

486 Nielsen, E.M., Andersen, M.T., 2003. Detection and characterization of verocytotoxin-producing
487 *Escherichia coli* by automated 5’ nuclease PCR assay. *J. Clin. Microbiol.* 41, 2884–2893.

488 Papa, A., 2019. Emerging arboviruses of medical importance in the Mediterranean region. *J. Clin.*
489 *Virol.* 115, 5–10.

490 Rogers, D.J., Randolph, S.E., 2006. Climate change and vector-borne diseases. *Adv. Parasitol.* 62, 345–
491 381.

492 Romo, H., Papa, A., Kading, R., Clark, R., Delorey, M., Brault, A.C., 2018. Comparative vector
493 competence of North American *Culex pipiens* and *Culex quinquefasciatus* for African and
494 European lineage 2 West Nile viruses. *Am. J. Trop. Med. Hyg.* 98, 1863–1869.

495 Schuffenecker, I., Peyrefitte, C.N., El Harrak, M., Murri, S., Leblond, A., Zeller, H.G., 2005. West Nile
496 virus in Morocco, 2003. *Emerg. Infect. Dis.* 11, 306.

497 Smithburn, K.C., 1942. Differentiation of the West Nile Virus from the Viruses of St. Louis and
498 Japanese B Encephalitis. *J. Immunol.* 43, 25–31.

499 Sule, W.F., Oluwayelu, D.O., Hernández-Triana, L.M., Fooks, A.R., Venter, M., Johnson, N., 2018.
500 Epidemiology and ecology of West Nile virus in sub-Saharan Africa. *Parasit. Vectors* 11, 414.

501 Sutherst, R.W., 2004. Global change and human vulnerability to vector-borne diseases. *Clin.*
502 *Microbiol. Rev.* 17, 136–173.

503 Tber Abdelhaq, A., 1996. West Nile fever in horses in Morocco. *Bull. Off. Int. Epizoot.* 108, 867–869.

504 Ulloa, A., Ferguson, H.H., Méndez-Sánchez, J.D., Danis-Lozano, R., Casas-Martínez, M., Bond, J.G.,
505 García-Zebadúa, J.C., Orozco-Bonilla, A., Juárez-Ordaz, J.A., Farfan-Ale, J.A., 2009. West Nile
506 virus activity in mosquitoes and domestic animals in Chiapas, México. *Vector-Borne Zoonotic*
507 *Dis.* 9, 555–560.

508 Vanhomwegen, J., Beck, C., Despres, P., Figuerola, A., García, R., Lecollinet, S., López-Roig, M.,
509 Manuguerra, J.-C., Serra-Cobo, J., 2017. Circulation of Zoonotic Arboviruses in Equine
510 Populations of Mallorca Island (Spain). *Vector-Borne Zoonotic Dis.* 17, 340–346.

511 Weaver, S.C., Charlier, C., Vasilakis, N., Lecuit, M., 2018. Zika, chikungunya, and other emerging
512 vector-borne viral diseases. *Annu. Rev. Med.* 69, 395–408.

513 Weaver, S.C., Reisen, W.K., 2010. Present and future arboviral threats. *Antiviral Res.* 85, 328–345.
514 Zannoli, S., Sambri, V., 2019. West Nile virus and Usutu virus co-circulation in Europe: epidemiology
515 and implications. *Microorganisms* 7, 184.
516 Zeller, H., Zientara, S., Hars, J., Languille, J., Mailles, A., Tolou, H., Paty, M.-C., Schaffner, F.,
517 Armengaud, A., Gaillan, P., 2004. West Nile outbreak in horses in southern France:
518 September 2004. *Eurosurveillance Wkly.* 8, 07.
519 Zeller, H.G., Murgue, B., 2001. The role of migrating birds in the West Nile virus epidemiology. *Med.*
520 *Mal. Infect.* 31, 168S–174S.
521

Table 1: Mosquito species, number of mosquitoes collected and virus detected by high-throuput chip based on the BioMark Dynamic arrays system.

| Collection Site | « GPS » coordinates | Biotope | Mosquito Species | Number of mosquitoes screened | Number of pools | Virus Detected through Microfluidic System | Type of confirmation Performed |
|-------------------------|--------------------------|--------------|---|-------------------------------|---------------------|--|-----------------------------------|
| Mohammedia | 33°38'22.4N 7°26'08.8W | Peri - urban | <i>Culex pipiens</i> | 670 | 67 | WNV* | WNV confirmed by Real time RT-PCR |
| Tanger | 35°46'44.3N 5°50'50.1W | Urban | <i>Culex pipiens</i> | 190 | 19 | – | – |
| Moulay bouselham | 34°52'28.7"N 6°17'14.5"W | Rural | <i>anoh detritus,</i> <i>Aedes caspius,</i> <i>culex pipiens,</i> <i>Anophele maculipennis</i> | 320 110 160 5 | 32 11 16 1 | – | – |
| Total | | | | 1455 | 146 | | |

WNV., West Nile virus; CHIKV., Chikungunya virus. (-) no virus detected and no confirmation performed. *WNV detected in one pool of *Cx.pipiens*.

Table 2: cELISA flavivirus results and WNV, USUV and TBEV results by MIA

| Number of samples | cELISA | | | MIA confirmation of positive cELISA results | | | | |
|---------------------------------|-----------------|-----------------|-----------------|--|-------------|-------------|-------------------|--------------------|
| Number of horses sampled | negative | Doubtful | Positive | WNV | USUV | TBEV | Flavivirus | WNV or USUV |
| 92 | 61 | 0 | 31(33.7%)* | 23 (25%)* | 2(2.1%)* | 0 | 4 (4.3%)* | 2 (2.1%)* |

* The percentage was based on total sample numbers (assuming all cELISA negative would also be negative by MIA)

Table 3: MNT confirmation of positive cELISA against WNV and USUV

| Number of samples | USUV | undetermined flavivirus | WNV | Distribution of WNV positive samples by titer (%) | | | | | |
|-------------------|------|-------------------------|------------|---|-----------|---------|----------------|-----------|--------------|
| 31 | 0 | 3 | 28 (30.4%) | 1:20 | 1:40 | 1:80 | 1:160 | 1:320 | >1:320 |
| | | | | 3 (3.3%)* | 2 (2,3%)* | 1 (1%)* | 11 (11,9%)* | 4 (4.3%)* | 7 (7.6%)* |

* The percentage was based on total sample numbers (assuming all cELISA negative would also be negative by MNT)